MACSF

COMMUNIQUÉS West-GlobeNewswire

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
18/06/2025
SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Bionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy
18/06/2025
SAN DIEGO, June 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) recently participated in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025. The event [...]
Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction
18/06/2025
Bolsters Prenetics’ pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term assets to approximately US$117 million Prenetics simplifies investment thesis as company focuses on high- [...]
Moleculin Participates in Virtual Investor “What This Means” Segment
18/06/2025
Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of [...]
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
18/06/2025
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the potential of [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18/06/2025
EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and [...]
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
18/06/2025
Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had [...]
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
18/06/2025
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc . ( [...]
F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim
18/06/2025
Data reinforce olorofim’s potential as a first-in-class treatment for patients with invasive fungal diseases and limited or no antifungal treatment options MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- [...]
Gradient Denervation Technologies Announces Acceptance into FDA’s Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
18/06/2025
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug [...]
Gradient Denervation Technologies annonce son admission au programme consultatif de la FDA sur le cycle de vie complet des produits pour le développement de son système de dénervation de l’artère pulmonaire
18/06/2025
PARIS, 18 juin 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies annonce ce jour son admission au programme pilote TAP (Total Product Life Cycle Advisory Program, programme consultatif sur le cycle de vie [...]
Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China
18/06/2025
BOSTON and SHANGHAI, June 18, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory [...]
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
18/06/2025
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita [...]
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
18/06/2025
DIAG723 is supported by a groundbreaking preclinical profile demonstrating its disease-modifying potential WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics , a biotechnology company focused on [...]
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
18/06/2025
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial [...]
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
18/06/2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data [...]
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
18/06/2025
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death [...]
Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) Investor Webinar with Presentation and Audience Q&A
18/06/2025
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi Medical” or the “Company”), is pleased to invite investors and other interested parties to attend the Company’s [...]
I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025
18/06/2025
Virtual investor event planned for July 8 th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at ESMO GI on July 2, [...]

Pages